Novel Nanostructured Lipid Carrier Co-Loaded with Doxorubicin and Docosahexaenoic Acid Demonstrates Enhanced in Vitro Activity and Overcomes Drug Resistance in MCF-7/Adr Cells - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Pharmaceutical Research Année : 2014

Novel Nanostructured Lipid Carrier Co-Loaded with Doxorubicin and Docosahexaenoic Acid Demonstrates Enhanced in Vitro Activity and Overcomes Drug Resistance in MCF-7/Adr Cells

Samuel Mussi
  • Fonction : Auteur
Rupa Sawant
  • Fonction : Auteur
Federico Perche
Mônica Oliveira
  • Fonction : Auteur
Ricardo Azevedo
  • Fonction : Auteur
Lucas Ferreira
  • Fonction : Auteur
Vladimir Torchilin
  • Fonction : Auteur

Résumé

To develop a nanostructured lipid carrier (NLC) co-loaded with doxorubicin and docosahexaenoic acid (DHA) and to evaluate its potential to overcome drug resistance and to increase antitumoral effect in MCF-7/Adr cancer cell line. The NLC was prepared by a hot homogenization method and characterized for size, zeta potential, entrapment efficiency (EE) and drug loading (DL). Drug release was evaluated by dialysis in complete DMEM, and NLC aggregation was assayed in the presence of serum. The cytotoxicity of formulations, doxorubicin uptake or penetration were evaluated in MCF-7 and MCF-7/Adr as monolayer or spheroid models.

Dates et versions

hal-02130734 , version 1 (16-05-2019)

Identifiants

Citer

Samuel Mussi, Rupa Sawant, Federico Perche, Mônica Oliveira, Ricardo Azevedo, et al.. Novel Nanostructured Lipid Carrier Co-Loaded with Doxorubicin and Docosahexaenoic Acid Demonstrates Enhanced in Vitro Activity and Overcomes Drug Resistance in MCF-7/Adr Cells. Pharmaceutical Research, 2014, 31 (8), pp.1882-1892. ⟨10.1007/s11095-013-1290-2⟩. ⟨hal-02130734⟩
13 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More